171 related articles for article (PubMed ID: 3607254)
1. Glucocerebroside storage in normal monocyte cultures.
Hardy B; Teitelman-Weissman B; Chazan S; Neri A
Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
[TBL] [Abstract][Full Text] [Related]
2. Animal and cellular models of Gaucher's disease. I. Refractoriness of thio analogs of glucocerebroside to enzymatic hydrolysis.
Quirk JM; Weis AL; Shapiro D; Brady RO
Biotechnol Appl Biochem; 1986 Feb; 8(1):96-100. PubMed ID: 3828086
[TBL] [Abstract][Full Text] [Related]
3. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
Sinclair GB; Jevon G; Colobong KE; Randall DR; Choy FY; Clarke LA
Mol Genet Metab; 2007 Feb; 90(2):148-56. PubMed ID: 17079175
[TBL] [Abstract][Full Text] [Related]
4. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.
Aflaki E; Stubblefield BK; Maniwang E; Lopez G; Moaven N; Goldin E; Marugan J; Patnaik S; Dutra A; Southall N; Zheng W; Tayebi N; Sidransky E
Sci Transl Med; 2014 Jun; 6(240):240ra73. PubMed ID: 24920659
[TBL] [Abstract][Full Text] [Related]
5. Gaucher disease: a century of delineation and research. Enzyme replacement therapy: model and clinical studies.
Beutler E; Dale GL
Prog Clin Biol Res; 1982; 95():703-16. PubMed ID: 7122644
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors and stimulators of glucocerebroside metabolism.
Radin NS
Prog Clin Biol Res; 1982; 95():357-83. PubMed ID: 6214799
[No Abstract] [Full Text] [Related]
7. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
[TBL] [Abstract][Full Text] [Related]
8. Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.
Choy FY; Bouillon L; Laurin CA
Am J Med Genet; 1987 Aug; 27(4):895-905. PubMed ID: 3425599
[TBL] [Abstract][Full Text] [Related]
9. An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells.
Naito M; Takahashi K; Hojo H
Lab Invest; 1988 May; 58(5):590-8. PubMed ID: 3367638
[TBL] [Abstract][Full Text] [Related]
10. Type 2 and type 3 Gaucher disease: a morphological and biochemical study.
Kaye EM; Ullman MD; Wilson ER; Barranger JA
Ann Neurol; 1986 Aug; 20(2):223-30. PubMed ID: 3752966
[TBL] [Abstract][Full Text] [Related]
11. Comparison of rates of hydrolysis of N-oleoyl and N-stearoyl glucocerebroside in patients with Gaucher's disease.
Peters SP; Aquino L; Naccarato WF; Gilbertson JR; Diven WF; Glew RH
Biochim Biophys Acta; 1979 Oct; 575(1):27-36. PubMed ID: 508779
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes.
Trajkovic-Bodennec S; Bodennec J; Futerman AH
Blood Cells Mol Dis; 2004; 33(1):77-82. PubMed ID: 15223015
[TBL] [Abstract][Full Text] [Related]
13. Assay of glucocerebrosidase using a fluorescent analogue of glucocerebroside for the diagnosis of Gaucher disease.
Midorikawa M; Okada S; Yutaka T; Yabuuchi H; Naoi M; Kiuchi K; Yagi K
Biochem Int; 1985 Sep; 11(3):327-32. PubMed ID: 4062951
[TBL] [Abstract][Full Text] [Related]
14. Gaucher's disease: a case history with extensive lipid storage in the brain.
Leech RW; Shuman RM; Putnam WD; Rance F; Jewett TT
Am J Clin Pathol; 1985 Apr; 83(4):516-9. PubMed ID: 3984948
[TBL] [Abstract][Full Text] [Related]
15. Status of enzyme replacement therapy for Gaucher disease.
Brady RO; Barranger JA; Gal AE; Pentchev PG; Furbish FS
Birth Defects Orig Artic Ser; 1980; 16(1):361-8. PubMed ID: 7004519
[TBL] [Abstract][Full Text] [Related]
16. Glucosylceramide and related compounds in normal tissues and in Gaucher disease.
Suzuki K
Prog Clin Biol Res; 1982; 95():219-30. PubMed ID: 7122635
[No Abstract] [Full Text] [Related]
17. A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse.
Willemsen R; Tybulewicz V; Sidransky E; Eliason WK; Martin BM; LaMarca ME; Reuser AJ; Tremblay M; Westphal H; Mulligan RC
Mol Chem Neuropathol; 1995; 24(2-3):179-92. PubMed ID: 7632321
[TBL] [Abstract][Full Text] [Related]
18. In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.
Prence EM; Chaturvedi P; Newburg DS
J Neurosci Res; 1996 Feb; 43(3):365-71. PubMed ID: 8714525
[TBL] [Abstract][Full Text] [Related]
19. Biochemical studies in a patient with subacute neuropathic Gaucher disease without visceral glucosylceramide storage.
Wenger DA; Roth S; Kudoh T; Grover WD; Tucker SH; Kaye EM; Ullman MD
Pediatr Res; 1983 May; 17(5):344-8. PubMed ID: 6856396
[TBL] [Abstract][Full Text] [Related]
20. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-α.
Mucci JM; Scian R; De Francesco PN; García FS; Ceci R; Fossati CA; Delpino MV; Rozenfeld PA
Gene; 2012 Nov; 509(1):51-9. PubMed ID: 23010424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
